Key facts
- Celltrio’s last known valuation is $113.5M (Jun 2025).
- It has raised $19.6M across 1 recorded rounds; the latest was Early Stage VC ($15.0M) in Jun 2025.
- Notable investors include Premier Partners, Asia2G Capital.
- Celltrio has filed 1 Form D with the SEC, most recently Jul 2025 ($15.0M sold to 1 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Celltrio
Funding rounds
1 roundsAbout Celltrio
Developer of a modular robotics system designed to support automated cell biology processes in life sciences. The company offers task-focused modules, digital recordkeeping, and cryogenic storage integration, enabling research laboratories and biopharmaceutical groups to maintain consistency, traceability, and workflow control.
- Sector
- Healthcare
- HQ
- Fremont, CA, United States
- Founded
- 2018
- Employees
- 26
- Website
- celltrio.com/
- Ownership
- Privately Held (backing)
Celltrio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Celltrio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Celltrio in its N-PORT filings yet. We sweep new filings monthly.